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Abstract
Background: Invariant Natural Killer T (iNKT) cells represent a determinant in the course of infections and diseases, however,
their role in the pathogenesis of non-infectious co-morbidities in HIV-positive patients is unknown.
Methods: Flow cytometry was used to investigate iNKT cell frequency, phenotype and function in HIV-infected patients on
HAART with bone and/or cardiovascular disorders and in HIV-positive controls free from co-morbidities.
Results: iNKT cells from subjects with bone and cardiovascular impairment expressed high levels of CD161 and
predominantly secreted TNF. iNKT cells from individuals with bone disease alone did not show any distinctive phenotypical
or functional characteristics. The functional capacity of iNKT cells in patients with cardiovascular disorder was impaired with
no cytokine release upon stimulation.
Conclusion: iNKT cells may have a role in non-infectious co-morbidities in treated HIV disease, possibly through the
exacerbation of inflammation. Further studies are needed to investigate iNKT cells in the pathogenesis of non-
communicable disorders in HIV infection.
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Introduction
HIV-positive patients on virologically-suppressive treatment are
at risk of non-infectious co-morbidities [1]. Indeed, HIV infection
is characterized by a state of persistent inflammation/immune
activation [2–4] known to predict clinical progression [5–8]; such
abnormalities are a distinctive characteristic of a senescent
immune system [9] which may accelerate the aging process in
the HIV-infected population [10–12]. In keeping with these
observations, HIV-positive patients with reduced Bone Mineral
Density (BMD) have been shown to feature a hyperactivated
peripheral T-cell phenotype [13]; similarly, HIV-infected subjects
with increased carotid Intima Media Thickness (IMT) and/or
positive history for cardiovascular disease show expansion of
activated CD8+CD38+ cells [14–17]. Most interestingly, T-cell
activation has been described an independent risk factor for
osteopenia/osteoporosis [13] and subclinical carotid abnormalities
[17,18].
While T-cell and monocyte activation has been extensively
investigated in the setting of non-infectious co-morbidities in
course of treated HIV disease and postulated as a possible marker
of ‘‘immunosenescence’’ in this patient population, very few
studies have investigated the role of other lymphoid cells in the
pathogenesis of non-infectious co-morbidities in HIV-infected
subjects.
Invariant natural killer T (iNKT) cells are a rare population of
T cells that possess qualities of both the innate and adaptive arms
of the immune response; iNKT cells recognize glycolipid antigens
presented by the non-classical MHC molecule CD1d [19–21] and
represent key components in the pathogenesis of many clinical
conditions [22–30].
Frequency and function of iNKT cells are impaired in the
course of HIV disease [31–35]. Indeed, iNKT cells express both
CD4 and the CXCR4/CCR5 co-receptors, thus representing a
target for the virus [36]. Accordingly, the CD4+ iNKT cell subset
is preferentially depleted in HIV disease [31,33,34,37] with a
parallel loss of IL-4 and IFN-c production [38] and such defects
are only partially restored by HAART [38–40]. Interestingly, the
production of Th1 cytokines from iNKT cells, such as IFN-c and
TNF has been inversely correlated with cell surface expression of
CD161 [32], thus suggesting that this molecule may represent a
marker of iNKT exhaustion in course of HIV [32].
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iNKT cells have also been implicated in atherogenesis [41–43];
indeed, in the mouse model, CD4+ iNKT cells are recruited to the
atherosclerotic lesions within arterial walls [44,45] and contribute
to the formation of fatty streaks [45–47]. Of note, CD1d is also
expressed in human atherosclerotic lesions [48,49] and lower
frequencies of iNKT were found in circulating blood of patients
with symptomatic atherosclerosis [49,50]. More specifically, iNKT
cells infiltrating human atherosclerotic tissue express CD4, CD161
and produce IFN-c [51] and seem to be implicated in plaque
stability through the interaction with vascular smooth muscle cells
[51].
Furthermore, in the mouse model, a-GalCer-activated iNKT
cells have been demonstrated to increase the frequency of
osteoclast progenitor cells and favour their maturation into
osteclasts [52]. The pro-osteocalstogenic effect of iNKT cells is
positively regulated by TNF, while IFN-c negatively affects this
process [52]. While specific iNKT subsets have been linked to
overt cardiovascular disease in humans [49,50], to our knowledge,
clinical findings on iNKT and osteopenia/osteoporosis in humans
have yet to be described.
In this report we investigated iNKT cell frequency, phenotype
and function in HIV-positive patients on virologically-suppressive
HAART with bone and/or cardiovascular impairment.
Our study is the first to show that iNKT cells from HIV-infected
individuals with cardiovascular and bone co-morbidities express
high levels of CD161 and predominantly secrete TNF, suggesting
a role in the pathogenesis of immunosenescent disorders in treated
HIV infection.
Materials and Methods
Study Patients
We consecutively recruited HIV-positive patients on virologi-
cally-suppressive HAART (HIV-RNA,40 cp/ml) with available
Bone Mineral Density (BMD; Dual-energy X-ray Absorptiometry-
DXA) and carotid Intima Media Thickness (IMT; ultrasonogra-
phy) measures for the screening of non-communicable disorders.
The research has been approved by the Ethical Committee of San
Paolo Hospital, Milan. All study participants provided written
informed consent. All study participants provided written
informed consent.
Bone disease was defined by the presence of osteopenia or
osteoporosis upon DXA scan: According to WHO criteria,
osteopenia and osteoporosis were defined by T-scores at the
lumbar spine and/or femoral neck that were ,21 SD and $2
2.5 and ,22.5, respectively [53]. Cardiovascular disease was
defined by either right and/or left carotid IMT.1 mm [54,55] or
presence of a carotid plaque upon ultrasonographic evaluation.
On the basis of lumbar/femoral BMD and carotid IMT values,
patients were divided into the following 4 groups: a) Double
Positive (DP) patients with both bone and cardiovascular
impairment (n = 10); subjects with Bone Disease (BD) (n = 10) or
Cardiovascular Disease (CD) (n = 10) alone; Double Negative
(DN) patients with neither bone nor cardiovascular disorders
(n = 10).
Human Lymphocyte separation and stimulation assays
Human peripheral blood (8 mL) was collected into EDTA tubes
and PBMCs were isolated using ficoll-paque (Biocoll separating
solution, BIOSPA). Cells of all patients were cultured in R10
medium alone (composition per 100 mL R10:88 mL RPMI,
10 mL fetal bovine serum, 1 mL [100 UI/mL] L-glutamine, and
1 mL [100 UI/mL] penicillin/streptomycin; Euroclone, Italy)
(unstimulated, US), or in medium supplemented with Phorbol
12-myristate 13-acetate (PMA, 50 ng/mL; Sigma-Aldrich, Milan,
Italy)/ionomycin (500 ng/mL; Sigma-Aldrich, Milan, Italy). In a
subgroup of 20 patients PBMCs were stimulated also with a-
GalactosylCeramide (a-GalCer, 200 ng/mL; Enzo Life Sciences,
NY, USA). Dose response curves were performed to determine the
optimal concentration of both stimuli.
Flow Cytometry
Parameters for inclusion of Natural Killer T surface
phenotype and functional data. As iNKT cell levels are very
low in peripheral blood, particularly during HIV infection, 1
million of total events (and never less than 500,000) were acquired
for each sample. Moreover, as previously performed [32] a
minimum of 20 events collected within the iNKT gate was
required for the data to be considered for functional data analysis.
Surface staining. For the measurement of iNKT cell
frequency and CD161 expression, freshly-isolated PBMCs were
incubated with CD1d-tetramer-a-GalCer-PE (a-GalCer) (Proim-
mune, Oxford, UK), anti-CD3-PE Cy7 (Beckman Coulter,
Fullerton, California, USA), anti-CD161-FITC (Mylteni Biotec,
Bologna, Italy) anti-Va24-biotin (Beckman Coulter, Fullerton,
California, USA), for 30 minutes at 4uC. Cells were then washed
with buffer (PBS with 0.5% bovine serum albumin and 2 mmol/
EDTA) and stained with streptavidin-Qdot 655 (Invitrogen,
Carlsbad, California, USA) for 30 minutes at 4uC, in the dark.
Cells were washed again and run on a FACS CANTO 2.6
cytometer (BD Bioscences, San Jose, California, USA).
Intracellular staining. For the measurement of intracellular
cytokine production, a separate aliquot of PBMCs was incubated
with R10 (unstimulated), PMA and ionomycin (n = 40) or a-
GalCer (n = 20), as described above. After 1 h at 37uC in 5% CO2,
Brefeldin A (BRFA) (10 mg/mL; Sigma-Aldrich, Milan, Italy,) was
added. After incubation for 14 h, the cells were washed and
surface stained as described above, with the exception of anti-
CD161. Cells were washed again and incubated with 1 mL of
FACS Lysing Solutions (BD Bioscences, San Jose, California,
USA) for 45 minutes at room temperature, in the dark and washed
prior to intracellular staining with anti-TNF-a-FITC (BD
Bioscences, San Jose, California, USA)/IFN-c-FITC (Beckman
Coulter, Fullerton, California, USA). After 30 minutes of
incubation at 4uC in the dark, samples were washed, run on a
FACS CANTO 2.6 cytometer and analyzed with FACS Diva
6.1.3 software.
Statistical analysis
Data were analyzed with GraphPad 5 PRISM software. Fisher’s
exact test, Chi-squared test, Mann-Whitney U-test, Kruskall-
Wallis followed by Dunn’s post hoc analysis and Wilcoxon tests
were used for statistics. Differences were considered statistically
significant at p,0.05.
Results
Patient characteristics
Forty HIV-positive patients with available BMD and carotid
IMT measurements were consecutively recruited at the Clinic of
Infectious and Tropical Diseases, San Paolo Hospital, University
of Milan. Subjects were divided into the following 4 groups
(Table 1): 10 Double Positive (DP) patients; 10 Bone Disease (BD);
10 Cardiovascular Disease (CD); 10 Double Negative (DN)
patients (Table 1). 3 patients in the BD group were diagnosed
with osteoporosis and 7 subjects in the CD group presented a
carotid plaque upon ultrasonography.
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Study subgroups were comparable in terms of demographic and
HIV-related parameters (Table 1).
Differences in BMD and IMT values were registered among
groups as per inclusion criteria (Table 1).
HIV-infected DP patients display high levels of CD161-
expressing iNKT cells
We used a tetramer-based gating strategy (Fig. 1A) to measure
iNKT cell frequencies in HIV-positive patients with bone and
cardiovascular impairment (Double Positive, DP) and in HIV-
infected subjects free from co-morbidities (Double Negative, DN).
The frequency of iNKT cells in peripheral blood was similar in
the two patient groups (DP:.007% [IQR:.003–.021]; DN:.005%
[IQR:.003–.015]; p = .88; Fig. 1C); interestingly, however, DP
patients exhibited significantly higher CD161-expressing iNKT
cells in comparison to DN patients (DP: 87.8% [IQR: 80.6–92] vs
DN: 56.3% [IQR 37.4–76.1]; p = .001; Fig. 1D), suggesting an
exhausted iNKT phenotype in HIV-infected subjects with bone
and cardiovascular impairment.
HIV-positive DP patients display high TNF production
from iNKT cells both constitutively and following
stimulation
Given that iNKT cells are able to produce a wide range of Th1
and Th2 cytokines, we determined the functional status of
circulating iNKT by measuring TNF and IFN-c directly ex vivo
and after stimulation with PMA/ionomycin (Figure 1E, F) and the
iNKT-specific stimulus a-GalCer (Fig. 1G, H).
Table 1. Patient characteristics.
Characteristic DP (n =10) BD (n=10) CD (n=10) DN (n=10)
Age, years (IQR) 50 (44–57) 44 (38–62) 45 (43–54) 42 (38–50)
Sex, F (%) 3 (30) 3(30) 3 (30) 5 (50)
Duration of HIV infection, mths (IQR) 82 (67–323) 96 (44–183) 198 (141–263) 189 (71–225)
HIV epidemiology, n (%)
MSM 2 (20) 2 (20) 3 (30) 4 (40)
Heterosex 6 (60) 3 (30) 3 (30) 6 (60)
IVD use 2 (20) 3 (30) 4 (40) 0 (0)
HCV-Ab, n (%) 1 (10) 3 (30) 3 (30) 0 (0)
Nadir CD4, cells/mmc (IQR) 89 (60–222) 210 (109–362) 232 (80–280) 321 (54–397)
White blood cells (1000/mmc) 5.6 (4.7–7.9) 5.6 (5.1–6.5)c 6.0 (5.4–8.1)e 4.7 (4.5–5.6)
Neutrophils (%) 56 (48.0–64.0) 56 (50.0–59.0) 56 (49.0–68.0) 52 (45.0–64.0)
Lymphocytes (%) 32 (26.0–39.0) 34 (30.0–40.0) 37 (24.0–41.0) 34 (26.0–40.0)
Monocytes (%) 7.8 (7.2–9.1) 7.2 (6.3–8.0) 8.2 (7.7–8.8) 9 (6.8–11.4)
Eosinophils (%) 2.7 (1.6–4.1) 1.8 (1.3–2.6) 1.9 (1.4–2.6) 1.6 (1.0–3.6)
Basophils (%) 0.6 (0.4–0.6) 0.7 (0.5–0.7) 0.5 (0.4–0.6) 0.5 (0.3–0.6)
Lymphocytes (n) 1928 (1375–2049) 1862 (1332–2179) 1919 (1675–2551) 1733 (1317–2239)
Zenith HIV RNA, log10 cp/mL (IQR) 5.4 (4.6–5.9) 5.6 (4.9–5.9) 5.3 (5.2–5.7) 5.0 (4.5–5.4)
AIDS diagnosis n (%) 4 (40) 3 (30) 0 (0) 3 (30)
Current CD4 counts, cells/mmc (IQR) 515 (308–575) 583 (379–716) 570 (517–798) 532 (354–614)
Current CD4 counts, % 26 (23–30) 33 (26–39) 32 (24–39) 30 (22–40)
Current HIV RNA, log10 cp/mL (IQR) 1.59 1.59 1.59 1.59
HAART duration, mths (IQR) 72 (63–149) 88 (45–123) 164 (56–180) 76 (52–130)
HAART regimen
PI (%) 2 (20) 3 (30) 3 (30) 6 (60)
NNRTI (%) 6 (60) 6 (60) 6 (60) 4 (40)
Other (%) 2 (20) 1 (10) 1 (10) 0 (0)
Tenofovir use (%) 7 (70) 8 (80) 8 (80) 9 (90)
DXA (IQR)
T-score femoral neck 21.55 (22.00221.10)a,f 21.80 (22.15221.35)c,d 20.25 (20.9021.35) 20.55 (20.9520.80)
T-score lumbar spine 21.75 (22.15221.48)a,f 22.10 (22.73221.45)c.d 20.25 (0.25–1.08) 0.00 (20.2520.43)
Carotid IMT, mm (IQR)
Left 1.04 (0.93–1.11)a,b 0.82 (0.6520.96) 1.05 (0.98–1.21)e 0.85 (0.8020.93)
Right 1.05 (0.96–1.25)a 0.87 (0.6520.97)c 1.11 (1.00–1.38)e 0.89 (0.8320.91)
DP: Double Positive; BD: Bone Disease; CD: Cardiovascular Disease; DN: Double Negative. MSM: Males Who Have Sex With Males. IVD: Intravenous Drug. HCV: Hepatitis C
Virus. HAART: Highly Active Antiretroviral Therapy; PI: Protease Inhibitor; NNRTI: Non-Nucleoside Retroscriptase Inhibitor. DXA: Dual-energy X-ray absorptiometry. IMT:
Intima Media Thickness. Data presented as: median (interquartile range, IQR) for continuous variables; absolute number (percentage) for categorical variables. p,0.05:
aDP vs DN; bDP vs BD; cBD vs DN; dBD vs CD; eCD vs DN; fCD vs DP.
doi:10.1371/journal.pone.0110287.t001
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Figure 1. iNKT cell phenotype and function in HIV-positive ‘‘Double Positive’’ (DP) and ‘‘Double Negative’’ (DN) patients. Gating
strategy of flow cytometry analysis for staining of iNKT cell frequencies, phenotype and intracellular cytokine production in a representative HIV-
positive individual (A); an example of staining for intracellular cytokines is also shown of a representative HIV-negative subject (B). PBMCs were gated
on lymphocytes, and iNKT cells were visualized as CD3+, Va24+ and CD1d-tetramer+. An example of CD161 surface staining is shown in the far right
iNKT in Non Infectious Co-Morbidities in Treated HIV
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Both DP and DN patients displayed a significant increase in
TNF production following PMA/ionomycin (p = .002 and
p = .027 respectively; Fig. 1E). Interestingly however, DP patients
showed higher, spontaneous release of TNF both prior to
stimulation (75.8% [IQR: 46.3–92.1] vs 49.1% [IQR: 24.4–
62.9]; p = .049; Fig. 1E) and following PMA/ionomycin stimula-
tion (DP: 82.6% [IQR: 65.9–93.9]; DN 59.4% [IQR: 41–76.1];
p = .019; Fig. 1E).
The functional capacity of iNKT in terms of INF-c production
did not differ between groups. Indeed, neither DP nor DN patients
displayed a significant response to PMA/ionomycin (DP us: 83.3%
[IQR: 52.2–87.1]; DP stim: DP: 84% [IQR: 48.6–100]; p = .58;
DN us: 73.3% [IQR: 24–84.7]; DN stim: 62.2% [IQR: 27.2–88];
p = .38; Fig. 1F); moreover, INF-c release from iNKT cells was
comparable between subjects both prior to (p = .24) and following
PMA/ionomycin (p = .19; Fig. 1F).
Given the differences in TNF production upon PMA/
ionomycin, we decided to evaluate iNKT functional capacity in
response to iNKT-specific stimulation with aGalCer in 5 patients
per group.
In keeping with the above mentioned findings, significantly
higher spontaneous TNF release was noted in DP patients (DP:
80% [IQR: 63.5–93.1]; DN: 52% [IQR: 37.8–69.8]; p = .047;
Fig. 1G), who tended to significant TNF production after a-
GalCer (p = .063). Accordingly, TNF release from a-GalCer-
activated iNKT cells was greater in DP subjects (DP: 92.3% [IQR:
88.3–100]; DN: 62.3% [IQR: 51.1–78.5]; p = .021; Fig. 1G).
While no differences were observed in terms of IFN-c
production upon PMA/ionomycin, a non-significant trend to
higher cytokine release was noted following a-GalCer stimulation
in DP compared to DN subjects (92.9% [IQR: 82–100]; 75%
[IQR: 60.3–89.5] respectively; p = .059; Fig. 1G).
Taken together, these findings suggest that iNKT cells from
HIV-infected patients with concurrent bone and cardiovascular
disease selectively produce high levels of TNF, both constitutively
and upon stimulation.
HIV-positive BD patients display normal iNKT cell
frequencies and CD161 expression
Given that HIV-positive patients with bone and cardiovascular
impairment present higher levels of CD161-expressing and TNF-
producing iNKT cells, we aimed to investigate the phenotype and
functional capacity of these cells in the two disorders separately.
We thus measured the frequency of total and CD161-expressing
iNKT cells in patients with Bone Disease (BD) and compared
them to patients free from co-morbidities (DN subjects).
Differently from what observed in patients with both bone and
cardiovascular disease, the frequency of total (BD:.007%
[IQR:.005–.019]; DN.005% [IQR:.003–.015], p = .34 Figure 2A),
and CD161-expressing iNKT cells (BD: 62.3% [IQR: 50.7–90.7];
DN 56.3% [IQR 37.4–76.1]; p = .25; Fig. 2B) were comparable in
the two groups.
HIV-positive BD patients display high levels of TNF and
IFN-c from iNKT cells following stimulation
The functional capacity of iNKT cells in patients with bone
disease was measured through the production of TNF and IFN-c
prior to and following stimulation with PMA/ionomycin (Fig. 2C,
D) and a-GalCer (Fig. 2E, F).
Both BD and DN patients displayed a significant increase in
TNF-producing cells following stimulation with PMA/ionomycin
(BD us: 72.8% [IQR: 48.7–77.6]; BD stim: 76.7% [IQR: 60.2–
89], p = .002: see above for DN values; Fig. 2C). A non-significant
trend to higher spontaneous TNF release was observed in BD
patients (p = .075) with no differences between study individuals
upon PMA/ionomycin (p = .11) (Fig. 2C).
In reference to IFN-c production, BD patients alone responded
significantly to PMA/ionomycin (BD us: 70.5% [IQR: 31.1–83.3],
BD stim: 81.6% [IQR: 48.3–89.4]; p = .049; Fig. 2D), with no
differences among groups prior to and following stimulation
(Fig. 2D).
Upon iNKT-specific a-GalCer activation, BD patients dis-
played a non-significant trend to an increase in TNF production
(BD us: 76.5% [IQR: 66.7–84]; BD stim: 87.5% [IQR: 78.2–
99.1]; (p = .063), (Fig. 2E), with a tendency to higher cytokine
release compared to DN subjects (p = .056; see above for DN
values) (Fig. 2E). Of note, the finding of higher spontaneous TNF
release in the BD patient group prior to a-GalCer stimulation
which was not detected prior to PMA/ionomycin may reflect the
smaller sample size in the former experimental condition (n = 5 vs
n = 10, respectively) (Fig. 2E).
Similarly, BD patients were characterized by a non-significant
trend to higher IFN-c production (DB us: 83.3% [IQR: 75–88.7];
BD: stim: 87.5% [IQR: 84.1–97.1]; p = .063; Fig. 2F) with no
differences in cytokine release upon specific iNKT-activation
(p = .095; Fig. 2F).
Taken together, the present findings suggest that HIV-positive
subjects with bone impairment, display a tendency to a more
activated functional profile of iNKT cells compared to DN
individuals.
HIV-positive CD patients display normal iNKT cell
frequencies and CD161 expression
We next evaluated the frequency of total and CD161-expressing
iNKT cells in HIV-infected patients with CD.
Similarly to what registered in patients with bone impairment
alone, CD and DN subjects displayed similar iNKT frequencies
(CD: 0.004% [IQR: 0.002–0.005]; see above for DN values
p = .17: Figure 2G) and proportion of CD161-expressing cells
(CD: 47.1% [IQR: 41–79.5]; see above for DN values p = 1.0)
(Fig. 2H).
HIV-positive CD patients display a highly activated and
functionally exhausted iNKT-cell phenotype
iNKT cell function was measured ex vivo and following PMA/
ionomycin (Fig. 2I, J) and a-GalCer stimulation (Fig. 2K, L).
plot. iNKT frequency were comparable in DP and DN groups (C). iNKT cell phenotype was analyzed through the ex vivo expression of CD161 in DP
(n = 10) and DN (n= 10) patients (D). DP subjects exhibited significantly higher levels of CD161 on iNKT cell surface compared to DN patients
(p = .001). iNKT cell function was measured through the production of TNF and IFN-c ex vivo (US) and following stimulation with PMA/ionomycin
(n = 10 per group) (E, F) and a-GalCer (n = 5 per group) (G, H). Although DP and DN patients significantly increased TNF production upon PMA/
ionomycin stimulation (p = .002 and p= .027 respectively), DP subjects showed higher TNF release both prior to (p = .049) and following PMA/
ionomycin (E). Study groups exhibited similar frequencies of IFN-c-producing iNKT cells both ex vivo and after stimulation with PMA/ionomycin (F).
DP patients were characterized by significantly higher TNF release both prior to (p = .047) and following stimulation with a-GalCer (p = .021) (G).
Similar results were obtained in terms of IFN-c production, with a trend to higher cytokine production in DP subjects following iNKT-specific
stimulation (p = .059) (H). FSC, Forward Scatter: SSC, Side Scatter. Each symbol represents an individual.
doi:10.1371/journal.pone.0110287.g001
iNKT in Non Infectious Co-Morbidities in Treated HIV
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e110287
Figure 2. iNKT cell phenotype and function in HIV-positive ‘‘Bone Disease’’ (BD), ‘‘Cardiovascular Disease’’ (CD) and ‘‘Double
Negative’’ (DN) patients. iNKT frequency was comparable among BD and DN groups (A). BD (n = 10) and DN (n= 10) showed similar CD161-
expressing iNKT cell frequencies (B) and a significant increase in TNF production following PMA/ionomycin stimulation (p = .002 and p= .027
respectively). Despite a trend to higher spontaneous TNF release in BD patients (p = .075), comparable cytokine levels were recorded upon PMA/
iNKT in Non Infectious Co-Morbidities in Treated HIV
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Compared to DN subjects, patients with CD presented
significantly higher TNF levels both prior to (CD us: 73.7%
[IQR: 66.2–84.7]; DN see above; p = .005; Fig. 2I) and following
mitogen stimulation (CD post PMA/ionomycin: 80.2% [IQR:
69.6–90.2]; DN see above p = .029; Fig. 2I). Of note however,
healthy patients alone were able to induce significant TNF release
upon PMA/ionomycin, suggesting a highly activated and
exhausted iNKT phenotype in HIV-patients with cardiovascular
disease.
Similarly, CD patients presented a non-significant trend to
higher post-stimulation IFN-c production from iNKT cells (86.9%
[IQR: 79.3–90.8]; p = .052; Fig. 2J; see above for DN values)
despite similar spontaneous cytokine release between groups (CD:
82.85% [IQR: 76.7–88.3]; see above for DN values p = .15;
Fig. 2J).
The study of the functional capacity of iNKT cells following
specific stimulation with a-GalCer revealed comparable TNF and
IFN-c production between subjects in all experimental conditions
(Fig. 2K, 2L).
Discussion
The objective of the present study was to assess whether HIV-
positive individuals on virologically-suppressive HAART with
bone and cardiovascular co-morbidities are characterized by
specific iNKT cell phenotype and function.
The key finding of our analysis is the expansion of CD161-
expressing and, TNF-secreting iNKT cells in subjects with
coexisting bone and cardiovascular impairment; a less clear iNKT
fingerprint was found in patients affected by single co-morbidities.
HIV-related T-lymphocyte activation has been postulated as a
possible driving force of premature osteopenia/osteoporosis [13]
and coronary heart disease [14–18]. HIV infection is also featured
by impaired iNKT cell frequency [31,33,34,36,37] and function
[32,35]. In HIV-negative cohorts, iNKT cells have been involved
in the pathogenesis of cardiovascular disease; recently a correlation
between the loss of an anti-inflammatory subset of gut-residing
CD4+ iNKT cells and systemic immune activation has been
described in HIV infection [37], providing evidence for the
contribution of this particular cell subset in the pathogenesis of
HIV disease and non-communicable co-morbidities.
This is the first report to describe a peculiar iNKT phenotype in
HIV-positive patients with concomitant early bone and cardio-
vascular disease, consisting of heightened CD161 expression. In
our cohort, DP patients appear to be older and present a lower
CD4 T-cell nadir, albeit not statistically significant when
compared to the other subject groups; these findings are in line
with literature data showing a higher prevalence of non-infectious
co-morbidities in the aging population and in patients with a
history of advanced HIV infection [10], thus reinforcing our
findings on a peculiar iNKT phenotype in this setting. Interest-
ingly, when analyzing subjects with either bone or cardiovascular
impairment, we did not observe differences in terms of iNKT
surface expression of CD161 between diseased and healthy
individuals. Given that CD161 up-regulation reflects a more
mature iNKT cell phenotype [56,57], our finding suggests the
preferential expansion of senescent circulating iNKT cells in HIV-
infected patients with multiple co-morbidities and not in individ-
uals with only one non-communicable disorder, although the
smaller sample size may affect data analysis in the latter groups.
CD161 is also expressed on NK and CD8+ T cells [58].
Interestingly CD161+ NK cells have been reported to infiltrate the
human atherosclerotic plaque [51]; to our knowledge, studies on
CD161-expressing CD8+ T cells in bone and cardiovascular co-
morbidities in course of physiological aging are currently lacking
and it would be interesting to assess the role of this subset in these
settings.
Heightened CD161 expression was also associated with
increased iNKT TNF release in patients with bone and
cardiovascular impairment. This is in contrast to previous reports
describing an inverse correlation between CD161 and cytokine
production from iNKT cells [32]; however participants in the
present study were all on virologically-suppressive HAART and
may have undergone iNKT restoration [38–40]. Indeed, our
findings suggest that these cells are capable of producing high
levels of TNF, which, in turn, may represent the major driver of
iNKT-mediated inflammation and exacerbate bone/cardiovascu-
lar co-morbidities.
In order to evaluate the role of iNKT cells in the pathogenesis of
bone and cardiovascular disease alone, we investigated their
functional capacity in patients with either bone or cardiovascular
impairment.
In keeping with the evidence of a pro-inflammatory milieu in
the pathogenesis of non-infectious diseases in course of HIV
[1,10,11], subjects with bone impairment showed a trend to higher
spontaneous ex vivo TNF secretion and a significant IFN-c
increase release after stimulation, Given the limited number of
patients enrolled and the weak statistical significance of such
findings we cannot draw definitive conclusions on the role of
iNKT cells in bone disease. iNKT cell expression of other
members of the TNF superfamily such as RANKL, known to be
involved in bone homeostasis, should be explored in such setting.
Finally, we concentrated on the role of iNKT cells in the
pathogenesis of cardiovascular disease. Individuals with athero-
sclerosis displayed higher TNF secretion, both constitutively and
after stimulation. However, upon stimulation, iNKT cells from
patients with vascular damage were not able to further release
TNF, possibly suggesting exhausted functional capacity.
In line with the role of IFN-c–producing iNKT cells in the
pathogenesis of atherosclerosis and plaque stability [45,51], we
also found a trend to higher IFN-c secreting iNKT in patients with
endothelial damage; this finding did not reach statistical signifi-
cance, possibly due to limited sample size.
In the attempt to control for differences in antigen presenting
cells in the PBMC mixtures, white blood cell count and formula
were analyzed in our study population. The finding of similar
percentages of circulating monocytes in all study patients suggests
that iNKT phenotype and function may not be affected by diverse
ionomycin (C). BD patients alone responded to PMA/ionomycin with significant IFN-c production following stimulation (p = .0488) (D). Significantly
higher TNF production was detected in BD subjects (p = .031) prior to a-GalCer stimulation. Upon a-GalCer stimulation, BD patients displayed a trend
to significant increases in TNF release (p = .063), leading to higher cytokine levels in this population (p = .056) (E). No significant differences were
noted in terms of IFN-c production following a-GalCer, although BD patients tended to significant cytokine production (p = .063) (F). CD and DN
showed comparable iNKT cell frequencies (G). CD (n = 10) and DN (n= 10) showed similar CD161-expressing iNKT cell frequencies (H). CD subjects
showed higher TNF release both prior to (p = .005) and following stimulation with PMA/ionomycin (p = .029). Of note, DN patients alone responded to
stimulation by significantly increasing TNF release from iNKT cells aspecific stimulation (p = .027) (I). In keeping with these results, the CD group
displayed a trend to higher IFN-c release after PMA/ionomycin stimulation (p = .052) (J). No statistical differences were noted between groups in
terms of iNKT function following specific activation with a-GalCer (K, L). Horizontal lines indicate median values. Each symbol represents an individual.
doi:10.1371/journal.pone.0110287.g002
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monocyte frequencies, albeit not ruling out possible differences
other antigen presenting cells.
Several limitations exist in this study. First, the lack of HIV-
negative controls; second, individuals with co-morbidities repre-
sent a heterogeneous population ranging from patients with
preclinical damage (i.e. osteopenia/increased IMT) to subjects
with overt disease (i.e. osteoporosis/carotid plaque). In this respect
however, our findings were confirmed even when comparing
patients with advanced disease (osteoporosis, n = 3; carotid plaque,
n = 7) to individuals free from both co-morbidities. Further, our
finding of similar iNKT function following mitogen and CD1d-
antigen (a-GalCer) stimulation is in contrast to previous literature
reports showing enhanced iNKT response to the former stimulus
[32], and possibly reflects the different sample size used in the 2
experimental conditions. Finally the present work cannot establish
a cause-effect relationship between activated iNKT and co-
morbidities in the absence of a temporal relationship; moreover we
cannot exclude that T-cell immune activation is driving the
changes within the iNKT subset, as recently suggested by
Fernandez et al. [59]. Future studies should also assess whether
CD4- and CD8-expressing iNKT cells play a different role in the
pathogenesis of non-infectious co-morbidities.
Despite these limitations, we show an increase in CD161-
expressing and TNF secreting iNKT cells in HIV-positive
individuals with bone and cardiovascular impairment, setting the
basis for future studies specifically designed to investigate the role
of iNKT cells in the pathogenesis of non-communicable co-
morbidities in course of HIV infection.
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